Bill Text: NY S01755 | 2025-2026 | General Assembly | Introduced
Bill Title: Requires any sponsor of a clinical trial in this state, including but not limited to, a pharmaceutical drug manufacturer, pharmaceutical drug wholesaler, academic medical center, voluntary group, federal agency or health care provider, that applies for a state grant to conduct such clinical trial, to conspicuously post certain information about such clinical trial on the department's website.
Spectrum: Partisan Bill (Democrat 2-0)
Status: (Introduced) 2025-01-13 - REFERRED TO HEALTH [S01755 Detail]
Download: New_York-2025-S01755-Introduced.html
STATE OF NEW YORK ________________________________________________________________________ 1755 2025-2026 Regular Sessions IN SENATE January 13, 2025 ___________ Introduced by Sens. PERSAUD, HOYLMAN-SIGAL -- read twice and ordered printed, and when printed to be committed to the Committee on Health AN ACT to amend the public health law, in relation to requiring clinical trials that apply for state grant funding to make certain information about such clinical trials public The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Article 2 of the public health law is amended by adding a 2 new title 9 to read as follows: 3 TITLE 9 4 CLINICAL TRIALS 5 Section 269-b. Definitions. 6 269-c. Grant requirements. 7 269-d. Posting requirements. 8 § 269-b. Definitions. For purposes of this title: 9 1. "clinical trial" shall have the same meaning as set forth in subdi- 10 vision two-b of section forty-nine hundred of this chapter. 11 2. "health care provider" shall mean a practitioner in an individual 12 practice, group practice, partnership, professional corporation or other 13 authorized form of association, a hospital or other health care institu- 14 tion issued an operating certificate pursuant to this chapter or the 15 mental hygiene law, a certified home health agency or a licensed home 16 care services agency, and any other purveyor of health or health related 17 items or services including but not limited to a clinical laboratory, a 18 physiological laboratory, a pharmacy, a purveyor of x-ray or imaging 19 services, a purveyor of physical therapy services, a purveyor of health 20 or health related supplies, appliances or equipment, or an ambulance 21 service. 22 § 269-c. Grant requirements. 1. Following the effective date of this 23 section, the commissioner shall require any sponsor of a clinical trial 24 in this state, including but not limited to, a pharmaceutical drug EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD05050-01-5S. 1755 2 1 manufacturer, pharmaceutical drug wholesaler, academic medical center, 2 voluntary group, federal agency or health care provider, that applies 3 for a state grant to conduct such clinical trial, to conspicuously post 4 certain information about such clinical trial on the department's 5 website. 6 2. To the extent disclosure is permitted under federal law, the infor- 7 mation posted in accordance with subdivision one of this section shall 8 include, but shall not be limited to, the following: 9 (a) the name of all clinical trial sponsors, funders and manufactur- 10 ers, including the name and contact information, as well as the institu- 11 tional affiliation, of all sponsors, co-sponsors and administrators; 12 (b) a summary of the purpose of the clinical trial, including, but not 13 limited to: (i) the name of the pharmaceutical drug being tested and its 14 active ingredients, if applicable; (ii) the type of clinical trial to be 15 conducted; (iii) the overall design of the study, including the statis- 16 tical method to be employed; (iv) the status or phase type of the trial; 17 (v) the inclusion and exclusion criteria; (vi) the treatment methods 18 used; (vii) all hypotheses tested by the trial; and (viii) the medical 19 condition or conditions being studied; 20 (c) the start date and end date of the clinical trial; and 21 (d) information pertaining to the clinical trial, including, but not 22 limited to potential adverse effects of the pharmaceutical drug or 23 biological product associated with the clinical trial. 24 3. The commissioner shall promulgate rules and regulations as deemed 25 necessary to aid in the collection and posting of the clinical trial 26 information required pursuant to this section and shall monitor the 27 department's website for compliance with the requirements of this 28 section. 29 § 269-d. Posting requirements. 1. Following the effective date of this 30 section, the commissioner shall require any health care provider offer- 31 ing a clinical trial in this state to conspicuously post certain infor- 32 mation about such clinical trial on their website. 33 2. To the extent disclosure is permitted under federal law, the infor- 34 mation posted in accordance with subdivision one of this section shall 35 include, but shall not be limited to, the following: 36 (a) the therapeutic intent of the clinical trial; 37 (b) the name of all clinical trial sponsors, funders and manufactur- 38 ers, including the name and contact information, as well as the institu- 39 tional affiliation, of all sponsors, co-sponsors and administrators; 40 (c) a summary of the purpose of the clinical trial, including, but not 41 limited to: (i) the name of the pharmaceutical drug being tested and its 42 active ingredients, if applicable; (ii) the type of clinical trial to be 43 conducted; (iii) the overall design of the study, including the statis- 44 tical method to be employed; (iv) the status or phase type of the trial; 45 (v) the inclusion and exclusion criteria; (vi) the treatment methods 46 used; (vii) all hypotheses tested by the trial; and (viii) the medical 47 condition or conditions being studied; 48 (d) the start date and end date of the clinical trial; and 49 (e) information pertaining to the clinical trial, including, but not 50 limited to potential adverse effects associated with the clinical trial. 51 § 2. This act shall take effect immediately.
